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INTROD UCTION
Carbamazepine, first synthesized in 1953, was in it ially mark eted in Europe
as an anticonvulsant. In 197 1 Dalby reported th e drug's psych otrop ic effec ts,
most no tably mood stabi lization, in patients with temporal lobe epilepsy (TLE)
(I). Other psychiatric applications such as th e treatment of affectively an d
behaviorally labil e patients are being explored. These stud ies are yie ldi ng dat a
relevant to the treatment and understanding of th e neu robiology of mental
illn ess. For this reason , fami liarity wit h car bamazep ine is becoming increasingly
important to psychiatrists .
CHEMISTRY AND PHARMACOLOGY
Ca rbamazepine is structurally sim ilar to th e tricyclic antidepressant imi -
p ramine (Fig. 1) (2,3). Plasma leve ls peak four to e ight hours afte r ing est ion ,
with 75 % of the drug bound to pla sma proteins. CSF levels a re dependent on th e
level of unbound drug in plasma. Metabolism occurs primaril y in the liver via th e
cytochrome P-450 oxi dase system , producing carbamazepi ne- l 0 , ll-epoxide
which is as active an d may reach levels up to half that of carba mazepine. This is
almost entire ly converted to carbamazepine-trans-l 0, l l -dihydrodiol by epoxide
hyd rolase before excretion in the urine (Fig 2) (4). T he epo xide is 50 %
protein-bound in p lasma (5).
Carbamazep ine induces hepatic en zymes, thus enhanc ing its ow n metabo-
lism . Therefore, the 30 -hour half-life of a single oral dose drops to 20 hours at
three weeks at 12 hours afte r several months. The half-life is reduced in patient s
who simultaneously ta ke other inducers of hepatic en zymes suc h as ph en oba rbi-
tal, p henytoin, or alcohol (4). Ca rbamazepine also enhances the metabo lism o f
phenytoin an d warfarin for th e same reason (6) .
CLINICAL GU IDELINES
T he most co m mon side effect is an a llergic skin rash whi ch occurs in 5% to
15% of treated patients (7) . T his ma y be accompanied by sore th roat , mucosal
u lce ration and low grade fever. Antihistamines can be effect ive in e lim inating
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Chlorpromazine Imipramine Carbamazepine
FIGURE 1. The tricyclic structure of carbamazepine resembles that o f imipramine
and, to a lesser extent, chlorpromazine. Carbamazepine blocks norepinephrine reup-
take but does not block dopamine receptors
a llergic symptoms, th ough th e rash may require di sco ntinuatio n of ca rba maze-
pine. Carbamazepine-induced agranulocytosis has recei ved much attention
because of its mortality rate of up to 50%. Howeve r , less th an thirty cases have
been reported (2). T h is id iosyncrat ic reacti on has a preva lence o f one in 20,000
to 40 ,000 and is unrelated to a harmless 25 % decrease in whi te ce ll co unt wh ich
is fairly co mmon (7). About 10% of pati ents receiving the drug develop a mild
dose-r elated leukopenia whic h resolves within the first four months. O f these,
app roxima tely 2% co nt inue with a persistent leukopenia which necessitates
di scontinu ation o f th erapy (2) . Neurotoxic side effec ts of ca r ba mazepine ma y
incl ude drowsin ess, ver t io , atax ia, diplopia , and blurred visio n . Patien ts ac utely
intoxicated on th e drug ca n exh ib it seda tio n , respiratory depression , hyper ir r i-
ta bi lity, and even se izures. Other side effects incl ude na usea and vomiting , and
hepato to xicit y ranging fr om mild e levation of serum transaminases to acute
hepatitis. In addition , ch ron ic ad m inistra t ion ca n also cause a condition resem-
bl ing the synd rome of inappropriate secretion of antidiuretic hormone
(SIADH) , with wat er retention , hyponatremia , an d possib le water int oxicatio n
(2).
T he in itial dose o f ca r ba mazepine in healthy adu lts is 200 mg o nce or twice
a day. This is increased by no more th an 20 0 mg a day to a tota l of200 mg t.i.d , A
ser um level should be chec ked afte r five days and dosage adj usted accordi ng ly
(7). The actui ty of th e patient di ctates how aggressive ly the dosage should be
increased, bu t th e appearance of neu rotoxi cit y is a clear indication fo r sma ller,
more gradual increments. Mainten an ce doses average about 1000 mg/day,
thoug h the ra nge may vary from 20 0 to 160 0 mg/ day (8). In pati ents who are
e lder ly or have live r di sease , dosage and increments should be appropriately
decreased. T herape ut ic se rum levels ra nge from 6- 12 JLg/ ml; neurotox ic side
effects are mo re frequent abo ve 10 JLg/ ml (2,4). Leve ls shou ld be checked
freque nt ly dur ing initial th erapy since 90% of enzy me induct ion occu rs in the
FIGURE 2. Metabolic pathway of carbamazepine. Both the epoxide and dihydrodiol are excreted in the urine.
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first month (7). Moreover, a complete blood cou nt and live r panel should be
ch ecked prior to and periodicall y during treatment (2).
NE UROLOGIC AND ENDOCRI NE APPLICATIO NS
Carbamazepine, a potent anticonvulsant is th e d rug of choice in temporal
lobe epilepsy (9), and a first-line drug in controlling grand mal se izures. It is also
effective in the treatment of trigeminal neuralgia and other chronic pain
syndromes (10- 13). Its antidiuretic properties have led to its use in managing
diabetes insipidus (10).
APPLICATIONS IN MOOD DISORDERS
Most psychiatric trials ofcarbamazepine have been co nd ucted with patients
with bipolar disorder, although some studies have included sch izoaffect ive
patients in their test groups. Beginning in the early 1970's Okuma et a l (15,16)
in Japan demonstrated that carbamazep ine is ben eficial in th e treatment of
acutely manic patients and in longterm prophylaxis against ma nia. In a double-
blind controlled study , Post et a l (17) at th e National In sti tu tes of Menta l Health
reported carbamazep ine 's clear efficacy over placebo in symptom re lief in seven
out of nine (88%) manic patients. Of th ese , four (57%) relapsed d uring p lacebo
ad m inistrat ion.
The drug's acute anti-ma nic efficacy is approx ima tely th at of chlorproma-
zine (18). In over half of treat ed patients, peak antiman ic effects were reached
within ten da ys of administrati on o f either ch lorp romazi ne or ca rbamazepine.
Carbamazepine also lowered scores on th e Clin ica l Global Im pressio n (CGI )
sca le on average as much as lithium (19). Lithium, howeve r , had a more
co nsiste nt anti-manic effect than ca rba mazepine: th e changes in CGI sco res
tended to cluster around the mean in patients t reated with lith ium, while the
mean CGI change in car bamazep ine -treated patients was largely d ue to a few
who responded extremely well. A double-blind 3-year study compa ring lith ium
(n = 27) and carbamazepine (n = 29) found both drugs effec tive in about two
thirds of treated patients (26). Peak symptom relief was reached with in three
months of treatment onset in both groups. The on ly striking difference between
the drugs was their relative dropout rates . Lithium-treated patien ts with more
schizophrenic or schizoaffective symptoms had a sign ificant ly higher d ropout
rate than carbarnazepine-treated patients (50 % vs. 20 %, respecti vely). In con-
trast, patients who demonstrated " classical" bipolar psych otic fea tures had a
lower dropout rate when treat ed with lithium (20 % vs. 35%, respect ive ly).
Investigators are attempting to define a population of pat ients who are
particularly responsive to ca rbamazepine and who, th erefore , would be consid-
ered prime candidates for this treatment early in th eir illn ess. Some patients
with a history of lithium resistance responded better when ca rbamazepine was
added to or substituted for lithium (17, 2 1). In two open clinical tria ls with
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bipolar and schizoaffective patients resistant to lithium and/or neuroleptic
maintenance (22,23), a total of 14 out of 21 (67 %) of those patients improved
when carbamazepine was added or substituted into their treatment regimen.
Observations that rapid-cycling bipolar patients respond well to car ba mazepine
(17,21,22,24) have yet to be demonstrated in controlled clinical trials .
The drug's therapeutic effect in depressed patients is somewhat less clear ,
with five of thirteen (38 %) bipolar patients showing marked improvement in
Post et aI's original report (17), and twelve of thirty-five (34 %) showing marked
improvement in a subsequent study which involved bipolar (n = 24) and unipo-
lar (n = 11) depressed patients (25). The antidepressant effect is related to
plasma levels of the epoxide metabolite rather than carbamazepine itsel f (26) .
The drug's time course of action in depression is similar to th at of tri cyclic
antidepressants (TCA's), with substantial improvements occurring after two
weeks and maximum effect after three weeks (27). Because TCA's are known to
induce more rapid cycling in some bipolar patients treated for depression (28) ,
carbamazepine may be considered as an alternative treatment in patients with a
history of rapid cycling or mania during TCA therapy. One depressed bipolar
patient with a history of TCA-induced mania despite lithium prophylaxis
responded well to carbamazepine without cycling into mania (29). A recent case
report described the successful treatment of a bipolar depressed patient using
carbamazepine and electroconvulsive therapy (30) .
OTHER PSYCHIATRIC APPLICATIONS
Carbamazepine was found to markedly decrease the severity and fr equen cy
of behavioral dyscontrol in some women with borderline personality d isorder
(30) . The patients often reported an enhanced ability to think before acting, a
phenomenon referred to as "reflective delay. " This resulted in fewer ang ry
outbursts, episodes of violence, and suicide threats or attempts during th e tria l
period. In contrast, the placebo group showed no such improvements, and seven
of eleven placebo patients (64 %) were removed from the trial early becau se o f
behavioral deterioration, compared with one of fourteen of th e car bamazepine
trials (7%). In addition, the drug has also proven helpful in th e treatment of
patients with mixed frontal lobe disease and schizophrenia or schizoaffective
disorder with affective or behavioral liability (31).
. Carbamazepine is more effective than placebo when used in conj unc tion
with haloperidol in the treatment of excited psychoses of schi zophrenic and
schizoaffective, as well as manic, patients (32). Because of this appa rent efficacy
in patients exhibiting more schizophrenic features (22) , the effect s of carbama-
zepine on the dopaminergic pathway have been studied by Po st et a l (33) . T hey
found that carbamazepine decreased probenecid-induced CSF accumulati on of
homovanillic acid (HVA), a dopamine metabolite, and had no effec t on base line
CSF concentrations of HV A. This is in contrast to neuroleptics which increase
both baseline and probenecid-treated HVA levels in CSF. This, in addition to
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the absence of reported cases of ta rdive dyskinesia, sugge sts th at carbamazepine
does not exert its effect by dopamine receptor blockade. T h is is consistent with
previous animal studies (34). Rather, th e drug ma y work by decreasing dopa-
mine turnover in the brain. Thus far , carbamazepine ha s not proven useful in
treating tardive d yskinesia (35).
DRUG INTERACTIONS
Two recent reports have demonstrated that ca rba mazepine can reduce
plasma levels of haloperidol when the two are administered simultaneously
(36,37). This ma y be due to hepatic enzyme induction resulting in accelerated
metabolism of haloperidol. Therefore, larger neuroleptic doses may be neces-
sary for the management of patients treated concurrently with ca r ba mazepine.
Another potential complicat ion of carbamazepine treatment is neurotoxic-
ity during coadministration with lithium (38). Patients may present with confu-
sion, drowsin ess , weakness, lethargy, coarse tremor, hyper reflexia , nystagmus,
and cerebellar ataxia. These symptoms can be seen in both lithium (39) and
carbamazepine toxicity (40). In this case , however, neurotoxicity may develop at
" nontoxic" plasma levels of each drug. Therefore , monitoring o f drug levels
ma y not protect patients agains t developing ad verse effec ts . Fortunately the
neurotoxicity is rapidly reversible following dis continuation of treatm ent. A
history of lithium-induced neurotoxicity is a prominent risk factor for th is
complication (38).
On the other hand, coadministration of carbamazepine and lith ium offers a
potentially beneficial interaction. Carbamazepine can induce wate r re tention
leading to hyponatremia and wat er intoxication (41 ,42). Lithium, on the other
hand, has been used to treat such water retention in SI ADH by inducing a
nephrogenic diabetes insipidus (43). These opposite effec ts on plasma sodium
and fluid balance can offset one another so that patients receiving lith ium in
addition to carbamazepine may be less likely to develop hyponatremia than
patients treated with carbamazepine alo ne (44).
The use of carbamazepine in conjunction with TCA's and monoamine
oxidase inhibitors (MAOI's) has not been systemat ically stu d ied . However , we
ca n make some inferences on the basis of carbamazepine' s structure and
pharmacology. The drug inhibits presynaptic reuptake of norepinephrine by
approximately 25 %, compared to 85 % in the case of imipramine (3). T herefore
car bamazepine should be used like other TCA's and started prior to or at the
same time as MAOI's when combination therapy is desired (45). Combined
TCA-MAOI treatment, while raising concerns about hyperten sive crisis, has
been extensively reviewed and found to be safe and efficac ious when adminis-
tered properly (46, 47) .
A number ofdrugs inhibit the metabolism of ca r ba mazepine and may cause
increased serum levels. These include ery th romycin , verapamil , diltiazem,
isoniazid, nicotine, and th e opiate propoxyphene (4) . T hroug h enzyme indue-
USE OF CARBAMAZEPINE FOR PSYCHIATRIC DISORDERS;' A REVI EW 69
tion car bamazepine decreases serum levels of phenytoin and warfarin as well as
doxycycline, sodium valproate, e thosux im ide, and clonazeparn (3,4).
THEORETICAL CONSlDERATIO S
The efficacy of ca rbamazep ine in the treatment of exci ted psych oses raises
questions about the neurobiology of psychiatric illness. In the late 1960 's it was
observed that dominant hemisphere TLE predisposes patients to psych osis,
whil e nondominant hemisphere TLE is associa ted with bipolar illness (48). This
study compared fifty TLE patients with psychotic features with fifty nonpsy-
chotic TLE patients. The presence of psychosis was inversel y co r related with
seizure activity . A more recent study found that II of 17 (65%) of T LE pat ients
and zero of seven generalized epileptics had at least one of th e e igh t Schneider-
ian first-rank symptoms for schizophrenia (49) . Dalby's study (I ) goes on to
demonstrate that TLE patients treated with carbamazepine had mar kedl y
reduced affective symptoms such as anxiety , paranoia, and aggressive beh avior
in 24 of 58 (44 %) patients. Moreover, several patients improved psychiatrically
despite a lack of seizure control. While nearly half of Dalby's epileptic patients
had structural brain abnormalities, most subsequent stud ies of th e psych otrop ic
effects of carbamazepine have screened out patients with str uc tura l or electro-
en cephalographic abnormalities.
Post et al (50) proposed a th eory of agitated psych osis wh ich involved a
phenomenon called " kind ling. " Repetitive subth reshold stimulatio n of the
limbic system produces a hyperexcitable " kind led " state in whic h mot or seizures
ma y be induced by stimulation that was previously non-seizurogenic . Reviewing
the literature on the effects of chronic administration of cocaine and other CNS
st im ulants, they noted that subjects developed hypersensivity ra ther than
tolerance to the effects of th ese substances on pathological behavior and
se izu res.
Carbamazepine, in addition to phenobarbital and diazepam, is very effec-
tive in blocking experimental electrically kindled amygda loid se izu res in a
variety of animal species (51). Ph enytoin , another potent anticonvul sant, is much
less effective in blocking kindled am ygdaloid seizures. Moreover, phenytoin
exh ibits no significant therapeutic effect on manic patients (52). T h is suggests
the possibility of a limbic focus for the generation of mania and other excited
psychoses. The mechanism may involve subthreshold kindling of limbic st ruc-
tures. The absence of structural and physiologic abnormalities in such patients
could be more reflective of instrumental limitations than th e absen ce of organic
pathology.
CO NCLUSIO NS
Carbamazepine, once used only in the treatment of epilepsy and neuropat-
hic pain, is becoming increasingly important in th e treatment of some psychiat-
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ric patients, but that group is not yet clearly defined. Because of potential
adverse effects and drug interactions, it should be administered j udicious ly in
selected patients who can be carefully monitored. Nevertheless, it is becoming
evident that for a certain subset of psychiatric patients, carbamazepine a lone or
in combination with .o ther drugs may prove to be the only effec tive treatment
that is currently available.
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